RegulationFast Track (United States), Priority Review (Australia), Priority Review (United States), Special Review Project (China), Breakthrough Therapy (United States)

Structure/Sequence

Molecular FormulaC19H17F2N3NaO5

InChIKeyNOSILXJBCIUPCT-KIUAEZIZSA-N

CAS Registry1051375-13-3

Clinical Trials associated with Cabotegravir sodium

NCT06854029

/ Not yet recruitingPhase 4IIT

Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phase that will include a concurrent implementation evaluation and a randomized control trial.

Start Date01 Jun 2026

Sponsor / Collaborator

Duke University

[+4]

NCT07346508

/ Not yet recruitingNot Applicable

Project SPEED - Streamlined Protocol for Early Engagement and Delivery of HIV Prevention With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol

Project SPEED (Streamlined Protocol for Early Engagement and Delivery of HIV Prevention) is a pragmatic, cluster randomized implementation study evaluating a nurse-driven model for delivering long-acting injectable cabotegravir (LAI-CAB) for HIV pre-exposure prophylaxis (PrEP) within local public health departments (LPHDs) in Missouri. Although LAI-CAB is a highly effective HIV prevention strategy, access remains limited in many rural and resource-constrained settings due to workforce shortages and barriers to specialty care.
In this study, LPHDs are randomized to either implement a structured nurse-led PrEP delivery protocol (SPEED intervention) or continue current standard practices. At intervention sites, trained registered nurses assess PrEP eligibility, provide HIV and sexually transmitted infection testing, administer LAI-CAB injections under standing orders, and support ongoing follow-up as part of routine public health services. Control sites continue their usual workflows without additional training or standardized PrEP delivery processes introduced by the study.
The study uses an effectiveness-implementation hybrid type III design and is guided by established implementation science frameworks to evaluate reach, adoption, implementation, and sustainability of the nurse-driven model. Participants receiving care at participating LPHDs are followed for up to 48 weeks.
Project SPEED aims to generate real-world evidence on whether a nurse-driven approach can expand access to long-acting HIV prevention in public health settings, particularly in rural and underserved communities, and to inform scalable strategies for broader implementation of LAI-CAB PrEP.

Start Date01 Apr 2026

Sponsor / Collaborator

KC CARE Clinic

NCT07390409

/ Not yet recruitingNot ApplicableIIT

ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.

The ALIGN study will evaluate the delivery of injectable Lenacapavir (LEN), a long-acting injectable formulation for HIV pre-exposure prophylaxis (PrEP), amongst adolescents and young people (aged 15-35 years) living within the Klipfontein-Mitchell's health sub-district of Cape Town, South Africa. LEN will be offered alongside injectable Cabotegravir long-acting (CAB LA), an injectable PrEP product already approved for use in South Africa, and oral PrEP (F/TDF) modalities (including intermittent dosing where appropriate), the current standard of care (SOC) biomedical HIV prevention in South Africa. Following counselling, participants will be able to choose which PrEP product (LEN, CAB LA, or oral PrEP) to initiate, with the option to switch at any future clinical visit, and followed for 18 months. These options will be offered from two types of delivery sites, namely public health facilities and established mobile service delivery trucks, where various forms of PrEP are currently delivered as part of outreach services and ongoing research studies (FastPrEP UCT HREC nr. 713/2021 and PrEPared to Choose 567/2023).
Lenacapavir (LEN) is a novel, first-in-class, multi-stage HIV-1 capsid inhibitor with high potency and a long half-life, allowing administration by subcutaneous injection twice yearly (1). The PURPOSE 1 study, a phase 3, double-blind, randomized, controlled trial involved adolescent girls and young women in South Africa and Uganda. Purpose 1 study found that none of the participants receiving twice-yearly LEN injection acquired HIV infection (1). Purpose 2, which was conducted amongst cisgender men who have sex with men, transgender, and non-binary populations, reported two incident infections amongst 2179 LEN users. CAB LA is an alternative long-acting injectable formulation administered by intra-muscular injection every two months. CAB LA efficacy and safety was established in the HPTN 083 and HPTN 084 studies, which indicated a 66% and 88% reduction in HIV risk compared to oral PrEP users respectively. The ongoing PrEPared to Choose study, conducted by this study team, (UCT HREC 567/2023) offers CAB LA and oral PrEP products and has demonstrated the feasibility and impact of many of the PrEP choice and delivery processes put forward in this protocol. As such, this study team has extensive experience in CAB LA and oral PrEP real-world delivery.
The ALIGN study will provide one of the first real-world (outside of the clinical trial research site) evaluations of LEN delivery with the view to evaluate firstly, what implementation strategies best support LEN initiation and persistence at the level of the PrEP provider and the PrEP user, and secondly, persistence (defined as consistent, uninterrupted use as prescribed) on LEN compared to alternative injectable products and SOC oral PrEP. The proposed study will utilise a hybrid implementation study design, with co-primary implementation and clinical aims, in the form of a non-randomised, quasi-experimental trial design. Findings from this study will be used to inform the anticipated LEN rollout into public health facilities (including ANC clinics) as well as the implementation of PrEP choice service delivery in a new era of expanded biomedical HIV prevention products. The addition of LEN will build on the experiences of implementing previous long-acting PrEP products (such as injectable long-acting Cabotegravir) and will generate practical insights to inform the scale of this innovative tool while national regulatory approvals are being sought. This will include working with communities to harness their insights and answering specific questions to support effective delivery and drive uptake and effective use of injectable PrEP (LEN and CAB LA).
Study purpose:
To evaluate the delivery strategies (public health facility and community-based) and potential impact of Lenacapavir (LEN) as PrEP, on the relative persistence of up to 3700 young people (aged 15-35 years) initiating on LEN compared to an alternative injectable product (CAB LA) and oral PrEP products (standard of care).
We hypothesize that people who select injectable PrEP will be more likely to persist on PrEP when compared with people who select oral PrEP, and further that injectable LEN will show enhanced persistence compared to injectable CAB LA.
Primary study objectives:
The primary objectives of this study are to distinguish PrEP persistence patterns across different PrEP modalities (oral PrEP vs injectable CAB vs injectable LEN as PrEP) and identify successful implementation strategies that will aid the provision of PrEP choice to adolescents and young people in South Africa from two distinct delivery platforms (public health facilities and mobile services).

Start Date29 Jan 2026

Sponsor / Collaborator

Desmond Tutu Hiv Foundation

[+3]

100 Clinical Results associated with Cabotegravir sodium

100 Translational Medicine associated with Cabotegravir sodium

100 Patents (Medical) associated with Cabotegravir sodium

1,170

Literatures (Medical) associated with Cabotegravir sodium

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for acne: pooled results from two 6-month studies

Article

Author: Tanghetti, Emil A. ; Wroblewski, Karol ; Ghannoum, Mahmoud ; Harper, Julie C. ; Kircik, Leon H. ; Baldwin, Hilary ; Draelos, Zoe D. ; Gold, Linda Stein

AIM:

Given the chronic nature of acne, two 6-month studies were conducted to evaluate the long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% gel (CAB)-the only approved triple-combination acne topical-and its effects on scarring/dyspigmentation in participants with moderate to severe acne.

MATERIALS AND METHODS:

Data were pooled from 2 identical, open-label, single-center studies conducted in participants (N = 50) aged ≥12 years with Investigator's Global Assessment (IGA) score of 3/4. Endpoints included change from baseline in IGA score, inflammatory/noninflammatory lesions, skin appearance (dryness, postinflammatory hyperpigmentation [PIH], postinflammatory erythema [PIE]), and scarring. Adverse events and tolerability (itching, burning, redness, swelling) were assessed.

RESULTS:

At week 24, 67% of participants achieved treatment success, and significant reductions from baseline in inflammatory (88%) and noninflammatory (68%) lesions were observed (p < 0.001, both). Significant reductions in scarring (33%), investigator- and participant-assessed PIH (71%; 78%, respectively), and PIE (77%; 77%, respectively) were demonstrated (p < 0.001, all). Most participants (>70%) reported no tolerability issues throughout the studies. Seven adverse events occurred; 4 were related to CAB, and 3 led to study discontinuation (BPO allergy [n = 2], irritant contact dermatitis to BPO [n = 1]).

CONCLUSIONS:

These findings suggest that CAB is an appropriate and effective topical option for the long-term treatment of acne vulgaris.

01 Mar 2026·SEXUALLY TRANSMITTED DISEASES

Patterns and Correlates of Initiation of Long-Acting Injectable Cabotegravir for Preexposure Prophylaxis: A Case-Control Analysis

Article

Author: Rossotti, Roberto ; Caruso, Enrico ; Luzi, Leonardo ; Burastero, Giulia ; Gennaro, Elisa Di ; Bana, Nicholas Brian ; Rezzonico, Leonardo Francesco ; Travi, Giovanna ; Puoti, Massimo ; Baiguera, Chiara ; Cavazza, Gabriele ; Merli, Marco

Abstract:

We conducted a case-control analysis to evaluate the determinants for initiating long-acting injectable cabotegravir (LACAB) as preexposure prophylaxis (PrEP) in a real-world setting with limited drug access. Individuals selected for LACAB experienced more side effects from oral PrEP, riskier sexual behavior, longer prior PrEP use, and a significantly higher incidence of STIs during follow-up. Despite this, LACAB was well tolerated, and discontinuation rates were low. Our findings support prioritizing LACAB for individuals most exposed to HIV and with low adherence to oral regimens, especially in contexts where logistical or economic constraints limit universal access to PrEP.

09 Feb 2026·CLINICAL INFECTIOUS DISEASES

Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility?

Communications

Author: Marzolini, Catia

167

News (Medical) associated with Cabotegravir sodium

27 Feb 2026

·www.drugs.com

Monthly Cabotegravir-Rilpivirine Injections Superior to Standard Oral ART for HIV With Adherence Challenges

FRIDAY, Feb. 27, 2026 -- Monthly injections of long-acting cabotegravir-rilpivirine are superior to standard oral antiretroviral therapy (ART) in persons with human immunodeficiency virus ( HIV ) and medication adherence challenges, according to a study published online Feb. 18 in the New England Journal of Medicine . Aadia I. Rana, M.D., from the University of Alabama at Birmingham, and colleagues enrolled 453 persons with HIV who had inadequate adherence to ART (a persistent HIV-1 RNA level of >200 copies per milliliter or loss to follow-up) to 24 weeks of adherence support, conditional economic incentives, and standard care with oral ART as part of step 1. Then, in step 2, the 306 participants achieving an HIV-1 RNA level of ≤200 copies per milliliter were randomly assigned to continue standard care (154 participants) or switch to monthly injections of long-acting cabotegravir plus rilpivirine with or without oral lead-in therapy (152 participants). The researchers reported that step 2 randomization was stopped early on the basis of the superiority of cabotegravir-rilpivirine to standard care at a prespecified analysis. By week 48, the cumulative incidence of regimen failure was 22.8 percent in the cabotegravir-rilpivirine group and 41.2 percent in the standard-care group. For adverse events, the cumulative incidence was 43.5 percent in the cabotegravir-rilpivirine group versus 42.4 percent in the standard-care group. Two participants in each group developed resistance-associated mutations with confirmed virologic failure. "These findings have the potential to validate a long-acting approach for this additional group of patients and could make a significant difference to people living with HIV and our goal of ending the epidemic," Kimberly Smith, M.D., head of research & development at ViiV Healthcare, said in a statement. Several authors disclosed ties to ViiV Healthcare, the maker of cabotegravir-rilpivirine. Abstract/Full Text Editorial (subscription or payment may be required)

Clinical ResultPhase 2siRNA

26 Feb 2026

·www.biospace.com

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

94% of adults on stable therapy maintained viral suppression with intravenous lotivibart dosed every four months in combination with long-acting cabotegravir These phase IIb results reinforce lotivibart’s ultra long-acting potential, with the trial progressing to evaluate a twice-yearly intravenous dosing interval LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study. 1 In adults living with HIV on stable therapy, a regimen of lotivibart (N6LS), a broadly neutralising antibody, administered every four months combined with monthly intramuscular (IM) long-acting cabotegravir (CAB LA), maintained viral suppression in 94% of participants receiving lotivibart intravenously (IV) and 82% subcutaneously (SC), compared with 88% in the standard of care group. These favourable data reinforce lotivibart’s ultra long-acting potential (dosing every four months or longer) and support the progression of the study, which will evaluate a twice-yearly IV dosing interval for lotivibart. Results were presented today at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, Colorado. Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: “These positive 12-month data from EMBRACE strengthen the evidence that lotivibart has the potential to be a part of an ultra long-acting HIV treatment regimen and support our efforts to evaluate lotivibart in a twice-yearly dosing interval. These results build on our legacy of developing innovative long-acting options for HIV treatment that offer greater choice for people living with HIV.” At the 12‑month interim analysis, lotivibart combined with CAB LA maintained viral suppression in a high proportion of adults living with HIV on stable therapy, with confirmed virologic failure observed in two participants (4%; n=2/50) from the IV group and three participants (6%; n=3/49) in the SC group, compared to one (4%; n=1/26) receiving a daily oral standard of care. Lotivibart was generally well tolerated, with participants in both groups reporting high acceptability through month 12. Mean perception of injection (PIN) scores for “bother of ISRs,” “physical impact,” “sleep” and “acceptability” remained “very acceptable” to “totally acceptable” throughout the study in both groups. Adverse events related to lotivibart were less common in the IV group (24%; n=12/50) compared with the SC group (53%; n=26/49). Higher grade (grade 3-4) infusion-site reactions were reported in 16% (n=8/49) of participants in the SC group, while none were reported in the IV group. These findings build on the six-month EMBRACE data presented at CROI 2025, which first showed that lotivibart, administered every four months in combination with monthly CAB LA, effectively maintained an undetectable viral load in adults living with HIV on stable therapy. About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. Shionogi became a ViiV shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com . About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com . Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q4 Results for 2025. Registered in England & Wales: GSK plc ViiV Healthcare Limited No. 3888792 No. 06876960 Registered Office: 79 New Oxford Street ViiV Healthcare Limited London GSK Medicines Research Centre WC1A 1DG Gunnels Wood Road, Stevenage United Kingdom SG1 2NY *On 20 January 2026, GSK plc and Shionogi & Co., Ltd announced that they have reached agreement together with Pfizer Inc. for the economic interest in ViiV Healthcare Limited currently held by Pfizer to be replaced with an investment by Shionogi. Completion of the transaction is subject to certain regulatory clearances in relevant markets, and is expected to occur during the first quarter of 2026. References 1 CP. Rolle et al. Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. Contacts ViiV Healthcare enquiries: Media: Kate Senter, +44 (0) 77 9670 7446 (London) Melinda Stubbee, +1 919 491 0831 (North Carolina) GSK enquiries: Media: Tim Foley, +44 (0) 20 8047 5502 (London) Sarah Clements, +44 (0) 20 8047 5502 (London) Kathleen Quinn, +1 202 603 5003 (Washington, DC) Alison Hunt, +1 540 742 3391 (Washington, DC) Investor Relations: Constantin Fest, +44 (0) 7831 826525 (London) James Dodwell, +44 (0) 20 8047 2406 (London) Mick Readey, +44 (0) 7990 339653 (London) Steph Mountifield, +44 (0) 7796 707505 (London) Sam Piper, +44 (0) 7824 525779 (London) Jeff McLaughlin, +1 215 751 7002 (Philadelphia) Frannie DeFranco, +1 215 751 3126 (Philadelphia)

Clinical ResultPhase 2

25 Feb 2026

·viivhealthcare.com

ViiV HEALTHCARE REPORTS POSITIVE 12-MONTH DATA SHOWING INVESTIGATIONAL BNAB LOTIVIBART (N6LS) MAINTAINS HIGH LEVELS OF VIRAL SUPPRESSION IN LONG-ACTING HIV TREATMENT REGIMEN

London, 25 February 2026 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study.1 In adults living with HIV on stable therapy, a regimen of lotivibart (N6LS), a broadly neutralising antibody, administered every four months combined with monthly intramuscular (IM) long-acting cabotegravir (CAB LA), maintained viral suppression in 94% of participants receiving lotivibart intravenously (IV) and 82% subcutaneously (SC), compared with 88% in the standard of care group. These favourable data reinforce lotivibart’s ultra long-acting potential (dosing every four months or longer) and support the progression of the study, which will evaluate a twice-yearly IV dosing interval for lotivibart. Results were presented today at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, Colorado.

Clinical ResultPhase 2

100 Deals associated with Cabotegravir sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D10548 D10549	Cabotegravir sodium	J05AR	DB11751

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	Canada	ViiV Healthcare Ltd.	21 Sep 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV-Associated Lipodystrophy Syndrome	Phase 1	United States	GSK Plc	01 May 2013
Hepatitis	Phase 1	United States	ViiV Healthcare Ltd.	01 Nov 2011
Herpesviridae Infections	Phase 1	-	ViiV Healthcare Ltd.	01 Sep 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06250504 (LAPIS, Pubmed \| BMC Public Health)	Phase 3	HIV Infections	40	choice of PrEP modality choices through community-based SRH services	cnzppdvrzs(zpxxydlmip) = iucsgheqpn bcbspaplvg (rrrtzagaqd ) View more	Positive	20 Jan 2026
NCT05374525 (PILLAR, CTgov)	Phase 4	HIV Infections	287	Cabotegravir OLI (Dynamic Implementation (DI) - PSP)	peomwoufmx(rdenihlurd) = xtjflvneiu fqxwaqblyz (zdqqsnjeoe, 0.77) View more	-	15 Dec 2025
				Cabotegravir OLI (Routine Implementation (RI) - PSP)	peomwoufmx(rdenihlurd) = dkdpipysky fqxwaqblyz (zdqqsnjeoe, 0.70) View more
NCT04542070 (SOLAR, Pubmed \| J Infect Chemother)	Phase 3	HIV Infections	396	Cabotegravir+rilpivirine (CAB+RPV) LA Q2M with a 1-month optional once-daily OLI of CABRPV) LA Q2M with a 1-month optional once-daily OLI of CAB+RPV	cxzvzaiuiy(apuwfzagoy) = getluwvbnz dqkrdxyyif (khbjxatixr ) View more	Positive	01 Dec 2025
				Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)	cxzvzaiuiy(apuwfzagoy) = ykdgvfhknd dqkrdxyyif (khbjxatixr ) View more
NCT05917509 (VOLITION, BusinessWire) Manual	Phase 3	HIV Infections	145	Vocabria + Rekambys (cabotegravir + rilpivirine LA (CAB+RPV LA))	djdwyrzwgz(gjyimnfxck) = clywoyxvcr rdpshfppfp (rukhaygsrr ) View more	Positive	14 Jul 2025
NCT04542070 (SOLAR, Pubmed \| J Infect Chemother)	Phase 3	-	670	Long-Acting Cabotegravir + Rilpivirine (CAB+RPV LA)	wqmvogfacz(noknzvtmef) = vrqudwkthd bwkaqrwjnu (zqcgzzmzsa ) View more	Positive	01 Jul 2025
				Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)	wqmvogfacz(noknzvtmef) = qdfifckpgq bwkaqrwjnu (zqcgzzmzsa ) View more
NCT03635788 (LATITUDE , CTgov)	Phase 3	HIV Infections	456	Oral CAB+CAB-LA Maintenance Dose+RPV-LA Loading Dose (Step 2 Arm A: LA ART)	ryvjreaijm = ghgupzupri usawpnnini (bjylxktqci, rdypkzfltv - rnbsdfyhcu) View more	-	24 Apr 2025
				Standard of Care (SOC) Oral ART (Step 2 Arm B: SOC)	ryvjreaijm = qiwxtqwwqk usawpnnini (bjylxktqci, ffyrpxulbp - sozdwdsrxo) View more
NCT04542070 (SOLAR, Pubmed \| J Acquir Immune Defic Syndr)	Phase 3	HIV Infections	687	Cabotegravir + Rilpivirine LA	knniqhldjd(urtpfvjczz) = ykldofecya mulvrjpvlf (ijbgvdlvrx, -4.50 to 4.00)	Positive	01 Apr 2025
				Bictegravir/Emtricitabine/Tenofovir Alafenamide	btgjocgjtf(fnajrndxbw) = yeqaqdhmkq vbplmfubca (zrdklbqock, -2.30 to +1.95) View more
NCT03497676 (IMPAACT 2017/MOCHA, Pubmed \| Lancet HIV)	Phase 1/2	HIV Infections	139	Long-acting Injectable Cabotegravir 600 mg + Long-acting Injectable Rilpivirine 900 mg	hsmykjctvr(wcstaovwvv) = 10.8% [95% CI 6.2-17.2] of all 139 participants in the evaluable analysis population had at least one adverse event of grade 3 or above by week 24 fzbblvypfv (zrohrqukir ) View more	Positive	01 Mar 2025
NCT04692077 (CTgov)	Phase 2	HIV Infections	9	CAB LA+Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet	niaqgjkwjl(idwawpdpck) = fntizlhfqo iflrrfvzgi (ersuhomcyn, 1.3) View more	-	29 Jan 2025
OPERA (BusinessWire) Manual	Not Applicable	HIV Infections	-	ApretudeApretude (cabotegravir long-acting (CAB LA))	rbdzbktyxj(csgvuixhng) = ftjgodwmgs sftndtbiuf (mvcuzsnnts )	Positive	16 Oct 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis